ReviewBMJ neurology open2020
Alzheimer's disease: from basic science to precision medicine approach.
Review in BMJ neurology open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Short-chain fatty acid-producing commensals: Key modulators of AD neuroinflammation via the microbiota-gut-brain axis.Current research in microbial sciences · 2026Review
- Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies.Nutrients · 2025Review
- Doxycycline: An essential tool for Alzheimer's disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Review
- Exploring interdisciplinary perspectives on the implementation ofJournal of Alzheimer's disease : JAD · 2025Article
- Biological determinants of blood-based biomarker levels in Alzheimer's disease: role of nutrition, inflammation, and metabolic factors.Frontiers in aging neuroscience · 2025Review
- Neural Networks of Knowledge: Ontologies Pioneering Precision Medicine in Neurodegenerative Diseases.Current neuropharmacology · 2025Review
- Recent Advances in Therapeutics for the Treatment of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2024Review
- Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research.eLife · 2024Review
- Digital Health Technologies for Alzheimer's Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort.The journal of prevention of Alzheimer's disease · 2024Review
- Alpha Synuclein: Neurodegeneration and Inflammation.International journal of molecular sciences · 2023Review
- Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective.Journal of Alzheimer's disease : JAD · 2023Review
- How useful are biomarkers for the diagnosis of Alzheimer's disease and especially for its therapy?Neural regeneration research · 2022Article
- Task-dependent learning and memory deficits in the TgF344-AD rat model of Alzheimer's disease: three key timepoints through middle-age in females.Scientific reports · 2022Article
- Methods for Stratification and Validation Cohorts: A Scoping Review.Journal of personalized medicine · 2022Article
- The Potential Role of Gut Microbiota in Alzheimer's Disease: From Diagnosis to Treatment.Nutrients · 2022Review
- Atrial cardiopathy and cognitive impairment.Frontiers in aging neuroscience · 2022Review
- Review
- Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework.Journal of Alzheimer's disease : JAD · 2022Article
- Artificial Intelligence for Alzheimer's Disease: Promise or Challenge?Diagnostics (Basel, Switzerland) · 2021Review
- An infrared spectral biomarker accurately predicts neurodegenerative disease class in the absence of overt symptoms.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common form of dementia in the elderly. Together with cerebral amyloid accumulation, several factors contribute to AD pathology including vascular alterations, systemic inflammation, genetic/epigenetic status and mitochondrial dysfunction. Much is now being devoted to neuroinflammation. However, anti-inflammatory drugs as numerous other therapies, mainly targeted on β-amyloid, have failed to show efficacious effects in AD. Timing, proper selection of patients, and the need for a multitarget approach appear to be the main weak points of current therapeutic efforts. The efficacy of a treatment could be better evaluate if efficient biomarkers are available. We propose here the application of precision medicine principles in AD to simultaneously verify the efficacy of a treatment and the reliability of specific biomarkers according to individually tailored biomarker-guided targeted therapies. People at risk of developing AD or in the very early phase of the disease should be stratified according to: (1) neuropsychological tests; (2) apolipoprotein E (ApoE) genotyping; (3) biochemical analysis of plasma and cerebrospinal fluid (CSF); (4) MRI and positron emission tomography and (5) assessment of their inflammatory profile by an integration of various genetic and biochemical parameters in plasma, CSF and an analysis of microbiota composition. The selected population should be treated with antiamyloidogenic and anti-inflammatory drugs in randomised, longitudinal, placebo-controlled studies using ad hoc profiles (eg, vascular profile, mitochondrial profile, etc…) If these criteria are adopted widely and the results shared, it may be possible to rapidly develop innovative and personalised drug treatment protocols with more realistic chances of being efficacious.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.